Related Experiment Video
Updated: May 14, 2026
Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood
Published on: February 6, 2018
Construction and characterization of a camelized, human, VH-based peptide vaccine against CD20 antigen
Jianbin Liu1, Yanguo Tan, Ranxing Zhang
1Air Force General Hospital, People's Liberation Army, 30 Fucheng Road, Haidian District, Beijing 100142, People's Republic of China. liu_jianbin@yeah.net
Aim:
The purpose of this study was to construct and characterize a camelized, human, heavy-chain variable (VH) fragment-based peptide vaccine against CD20 antigen.
Materials & Methods:
Camelized, human VH with improved solubility and stability was used as a vaccine scaffold. A CD20 B-cell epitope was introduced into the complementarity determining region 3 of the engineered VH and a measles virus-derived T-helper epitope was grafted into the complementarity determining region 3. The chimeric VH fragment was synthesized in bacteria and purified for immunization of mice. The titers and antigen-binding specificity of the antibody elicited by the chimeric peptide vaccine were assessed in vitro.
Results:
Notably, the CD20 epitope within the chimeric VH peptide elicited high-titered anti-CD20 antibody. Besides binding to GST-CD20 fusion protein, the antibody was cross-reactive with the native CD20 antigen on Raji cells.
Conclusion:
In conclusion, the chimeric VH peptide vaccine consisting of the CD20 epitope can induce the production of the CD20-specific antibody, likely having potential implications in preventing CD20 overexpression cancers.
